49 results
6-K
EX-5.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
investigation or verification in respect of those assumptions:
(a)all original documents examined by us are authentic and complete;
(b)all copy documents … , and we have not, for the purposes of this opinion, made any investigation of the laws of any other jurisdiction, and we express no opinion
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
shall mean any action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding … or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
for inspection or investigation; (ii) the PCAOB shall have direct access to interview or take testimony from all personnel of the audit firms whose issuer … audit documentations located in China or Hong Kong to the PCAOB for inspection or investigation, or the PCAOB expands the scope of the Determination so
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
shall have independent discretion to select any issuer audits for inspection or investigation; (ii) the PCAOB shall have direct access to interview … or investigation, or the PCAOB expands the scope of the Determination so that we are subject to the HFCA Act, as the same may be amended, you may
F-3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
5 Dec 23
Shelf registration (foreign)
4:06pm
, or the Sarbanes-Oxley Act, the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation; (ii) the PCAOB shall … Kong to the PCAOB for inspection or investigation, or the PCAOB expands the scope of the Determination so that we are subject to the HFCA Act
6-K
EX-4.1
ngzd74aaqwyrckntpv5
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
xc5wwsar
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
424B3
trmmgsty
31 Mar 23
Prospectus supplement
4:04pm
424B3
w9431m7g
2 Dec 22
Prospectus supplement
4:17pm
F-1
o6reyoao97r 06y6
18 Nov 22
Registration statement (foreign)
5:39pm
F-1
EX-5.1
ppvwst
18 Nov 22
Registration statement (foreign)
5:39pm
6-K
EX-10.1
rqt1 8atrsaz
18 Nov 22
Current report (foreign)
5:20pm
6-K
EX-10.1
q5rzfrsq
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
6-K
EX-10.3
hwdakknf7a7ekeqnvo
8 Nov 22
Virax Biolabs Group Limited Announces $3.8 Million Private Placement
4:56pm
20-F
4pc20j
12 Aug 22
Annual report (foreign)
4:20pm
6-K
EX-1.1
xd9zrnzs h70
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.5
6dmr9yargsdiu5x3
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.4
d5g8fb4fz2zljd6
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-14.1
lhmmo
26 Jul 22
Current report (foreign)
7:36am